Poolbeg Pharma PLC Registered Shares LS -,0002
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
126.42%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.01 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 0.062 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:55:55 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 0.065 | 0.06 |
| PREV. DAY'S PRICE | 0.06 | (07/20) |
| CHANGE DAY BEFORE | +0.00 | 3.33 % |
| 52 WEEK HIGH / LOW | 0.105 (06/04) | 0.0205 (08/04) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027 | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.01 | -0.01 | -0.01 | -0.01 | - |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 3.13 | 3.83 | 3.24 | - | - |
PRICE - SALES RATIO | - | - | - | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A3CVN5 |
| ISIN | GB00BKPG7Z60 |
| SYMBOL | 7JN |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | POOLBEG PHARMA LS -,0002 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -16.67 % | -17.81 % | 53.85 % | 44.58 % | 126.42 % | -22.08 % | - | 60.00 % |
| HIGH | 0.08 | 0.08 | 0.11 | 0.11 | 0.11 | 0.17 | - | 0.11 |
| LOW | 0.06 | 0.06 | 0.03 | 0.02 | 0.02 | 0.02 | - | 0.02 |
Dividende
pro Aktie
POOLBEG PHARMA LS -,0002 does not deliver dividend information
Company profile
Poolbeg Pharma Plc is a clinical-stage biopharmaceutical company, which focuses on the development of innovative medicines to address unmet medical needs. The firm's capital light clinical model enables to develop multiple products faster than the traditional biotech model. Its portfolio includes POLB 001, Phase II ready, repositioned small molecule immunomodulatory for severe influenza, along with a vaccine discovery platform, PredictViral biomarker platform, and the disease progression data & bio banks that will be interrogated using AI platforms. The company was founded on March 19, 2021 and is headquartered in London, the United Kingdom.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.